Communiqués EQL Pharma AB

Actions

EQL

SE0005497732

Pharmacies

Marché Fermé - Nasdaq Stockholm 18:00:00 01/10/2026			Varia. 5j.	Varia. 1 janv.
22,70 ^SEK	-1,30%		-1,30%	-60,73%

20/08	EQL Pharma AB (publ) nomme Niraj Kumar en tant que nouveau membre du conseil d'administration	CI
17/08	EQL Pharma : le directeur financier Allan Sylvest Aasberg procède à son premier achat d'actions	FW

Communiqués

20/08	Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026	AQ
14/08	EQL Pharma: Improvement emerging, confirmation needed – Q1 review	AQ
12/08	Memprex© (methenamine hippurate) license signed with partner for Hungary	AQ
07/08	EQL Pharma: Soft start as expected, guidance intact	AQ
07/08	Interim Report April - June 2026	AQ
28/07	EQL Pharma: Soft start to back-end loaded year – Q1 preview	AQ
27/07	EQL Pharma recruits Oskar Karmlid as new Chief Supply Chain Officer (CSCO)	AQ
24/07	EQL Pharma Annual Report 2025/2026	AQ
17/07	Notice of annual general meeting in EQL Pharma AB	AQ
15/07	Mellozzan® (melatonin) approved in Kazakhstan	AQ
13/07	Memprex© (methenamine hippurate) license signed with partner for Spain	AQ
10/07	Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2026/27	AQ
15/06	Methenamine hippurate (brand name Cystohipp©) has been launched in Germany	AQ
11/05	EQL Pharma: Near-term reset; solid execution needed to rebuild the case	AQ
08/05	EQL Pharma: Better-than-feared Q4 overshadowed by cautious outlook	AQ
08/05	Year-end Report April 2025 - March 2026	AQ
27/04	EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO)	AQ
22/04	Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26	AQ
20/04	EQL Pharma: Recovery continues, but near-term headwinds – Q4 preview	AQ
27/03	EQL Pharma CEO sells shares to finance capital gains tax from option redemption	AQ
25/03	Mellozzan® (melatonin) has been approved in Italy	AQ
12/02	Nomination committee for the 2026 Annual General Meeting	AQ
04/02	EQL Pharma: Solid Q3 with branded-driven EBIT beat – worst behind it	AQ
03/02	EQL Pharma: Q3 2025/26 initial: Beat driven by strong branded sales	AQ
03/02	Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026	AQ